mircera mthoxy polythylne glycol-potine bta

Submit Demands Online

Mircera (methoxy polyethylene glycol-epoetin beta) 1 NAME OF THE MEDICINE Methoxy polyethylene glycol-epoetin beta 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Mircera 30 micrograms/0 3 mL solution for injection in pre-filled syringe Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) Injectiion Company: Hoffman La-Roche Application No : 125164 Approval Date: 11/14/2007 Approval Letter(s) (PDF) Printed Labeling (PDF) Officer/Employee List (PDF) Office Director Memo

Methoxy polyethylene glycol

Methoxy polyethylene glycol-epoetin beta (Mircera) is a continuous erythropoietin receptor activator with a long half-life (approximately 130 hours) In patients with anaemia associated with chronic kidney disease (CKD) both on and not on dialysis who had not

Page 1 of 6 Clinical Policy: Methoxy polyethylene glycol-epoetin beta (Mircera) Reference Number: CP PHAR 238 Effective Date: 0 7 01 16 Last Review Date: 05 20• Adult patients on dialysis and patients not on dialysis • Pediatric patients 5 to 17 years of age on

2 Please see full Prescribing Information including Boxed WARNING and Medication Guide for Mircera (methoxy polyethylene glycol-epoetin beta) Injection for Intravenous or Subcutaneous Use INDICATIONS AND USAGE3 Mircera is an erythropoiesis-stimulating

Epoetin beta and methoxy polyethylene glycol is a combination medicine used to treat anemia (lack of red blood cells) and to reduce the need for blood cell transfusions Epoetin beta and methoxy polyethylene glycol is used to treat anemia caused by chronic kidney disease in adults or in children at least 5 years old who are on hemodialysis

MIRCERA (methoxy polyethylene glycol-epoetin beta) Non-Dialysis Prior Authorization Criteria Proprietary Information Restricted Access – Do not disseminate or copy without approval 2020 Magellan Rx Management Medicaid Services Inc Updated on 12

Mircera (methoxy polyethylene glycol

2017/9/25Mircera contains the active ingredient methoxy polyethylene glycol-epoetin beta and belongs to a group of medicines known as hormones The kidneys produce the natural hormone erythropoietin which stimulates the production of red blood cells in the bone marrow and spleen

DESCRIPTION Mircera methoxy polyethylene glycol-epoetin beta is an ESA which differs from erythropoietin through formation of a chemical bond between either the N-terminal amino group or the ε-amino group of any lysine present in erythropoietin predominantly Lys 52 and Lys 45 and methoxy polyethylene glycol (PEG) butanoic acid (approximately 30 000 daltons)

Indications for MIRCERA (methoxy polyethylene glycol-epoetin beta injection solution) refers to the medical reasons for why Mircera is used and recommended as a treatment Trending videos Doctors and patients discuss the latest medical treatments and health tips Drugs A-Z Search prescription drugs for why they're used side effects and more

DESCRIPTION Mircera methoxy polyethylene glycol-epoetin beta is an ESA which differs from erythropoietin through formation of a chemical bond between either the N-terminal amino group or the ε-amino group of any lysine present in erythropoietin predominantly Lys 52 and Lys 45 and methoxy polyethylene glycol (PEG) butanoic acid (approximately 30 000 daltons)

Medscape - Anemia associated with chonic kidney disease dosing for Mircera (methoxy polyethylene glycol / epoetin beta) frequency-based adverse effects comprehensive interactions contraindications pregnancy lactation schedules and cost information 10

Methoxy Polyethylene Glycol-Epoetin Beta Methoxy polyethylene glycol-epoetin beta is a chemically synthesized substitute analog of erythropoietin with receptor binding kinetics that are different from other ESAs and it has a very low plasma clearance From: Chronic Kidney Disease Dialysis and Transplantation (Third Edition) 2010

MIRCERA (methoxy polyethylene glycol-epoetin beta) Non-Dialysis Prior Authorization Criteria Proprietary Information Restricted Access – Do not disseminate or copy without approval 2020 Magellan Rx Management Page 2 | • Functional iron deficiency (i e

MIRCERA (methoxy polyethylene glycol-epoetin beta) Non-Dialysis Prior Authorization Criteria Proprietary Information Restricted Access – Do not disseminate or copy without approval 2020 Magellan Rx Management Page 2 | • Functional iron deficiency (i e

Mircera (methoxy polyethylene glycol / epoetin beta)

Medscape - Anemia associated with chonic kidney disease dosing for Mircera (methoxy polyethylene glycol / epoetin beta) frequency-based adverse effects comprehensive interactions contraindications pregnancy lactation schedules and cost information 10

1 Mircera 190530 AUSTRALIAN PRODUCT INFORMATION Mircera (methoxy polyethylene glycol-epoetin beta) 1 NAME OF THE MEDICINE Methoxy polyethylene glycol-epoetin beta 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Mircera 30

2017/9/25Mircera contains the active ingredient methoxy polyethylene glycol-epoetin beta and belongs to a group of medicines known as hormones The kidneys produce the natural hormone erythropoietin which stimulates the production of red blood cells in the bone marrow and spleen

Epoetin beta and methoxy polyethylene glycol is a combination medicine used to treat anemia (lack of red blood cells) and to reduce the need for blood cell transfusions Epoetin beta and methoxy polyethylene glycol is used to treat anemia caused by chronic kidney disease in adults or in children at least 5 years old who are on hemodialysis

Mircera is a long-acting erythropoietin stimulating agent (ESA) used for the treatment of symptomatic anaemia associated with chronic kidney disease (CKD) in adult patients 1 It is the first Continuous Erythropoietin Receptor Activator (C E R A ) 2 It works like the human protein erythropoietin to help the body make more red blood cells and is used to reduce or avoid the need for red blood

Page 1 of 4 Clinical Policy: Methoxy Polyethylene Glycol-epoetin Beta (Mircera) Reference Number: ERX SPA 323 Effective Date: 02 19 19 Last Review Date: 05 19 Non-FDA approved indications which are not addressed in this policy unless there is sufficient

Mircera (methoxy polyethylene glycol-epoetin beta) injection April 15 2019 This notice provides information for 340B Covered Entities regarding the distribution of Mircera (methoxy polyethylene glycol-epoetin beta) which is marketed by Vifor Pharma Mircera is

Mircera is a long-acting erythropoietin stimulating agent (ESA) used for the treatment of symptomatic anaemia associated with chronic kidney disease (CKD) in adult patients 1 It is the first Continuous Erythropoietin Receptor Activator (C E R A ) 2 It works like the human protein erythropoietin to help the body make more red blood cells and is used to reduce or avoid the need for red blood

Methoxy Polyethylene Glycol-Epoetin Beta Methoxy polyethylene glycol-epoetin beta is a chemically synthesized substitute analog of erythropoietin with receptor binding kinetics that are different from other ESAs and it has a very low plasma clearance From: Chronic Kidney Disease Dialysis and Transplantation (Third Edition) 2010